Letetresgene autoleucel (lete-cel, GSK3377794) + Cyclophosphamide + FLUDARABINE
2 treatments and conditions followed through the public trial records. Not medical advice. How a status is set
Treatments and conditions
| Treatment and condition | Where it stands | Trials |
|---|---|---|
| Letetresgene autoleucel (lete-cel, GSK3377794) + Cyclophosphamide + FLUDARABINE for liposarcoma, myxoid | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Letetresgene autoleucel (lete-cel, GSK3377794) + Cyclophosphamide + FLUDARABINE for sarcoma, synovial | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |